Clinical Research Directory
Browse clinical research sites, groups, and studies.
Safety Study of MultiGeneAngio in Patients With Chronic Critical Limb Ischemia
Sponsor: MultiGene Vascular Systems Ltd.
Summary
The purpose of this study is to evaluate the safety and activity of two doses of MultiGeneAngio, a cell therapy product produced from the patient's own cells, as potential treatment for patients with chronic critical limb ischemia.
Official title: Phase I/IIa Safety, Two-dose Study of MultiGeneAngio in Patients With Chronic Critical Limb Ischemia
Key Details
Gender
All
Age Range
50 Years - 90 Years
Study Type
INTERVENTIONAL
Enrollment
28
Start Date
2010-02
Completion Date
2026-05
Last Updated
2015-03-05
Healthy Volunteers
No
Interventions
MultiGeneAngio
Low-therapeutic dose of MultiGeneAngio in suspension administered as one treatment, intra-arterially
MultiGeneAngio
Intermediate-therapeutic dose of MultiGeneAngio in suspension administered as one treatment, intra-arterially
Locations (7)
Barzilai Medical Center
Ashkelon, Israel
Soroka Medical Center
Beersheba, Israel
Rambam Medical Center
Haifa, Israel
Shaare Zedek Medical Center
Jerusalem, Israel
Hadassah University Hospital, Ein Kerem
Jerusalem, Israel
Kaplan Medical Center
Rehovot, Israel
Chaim Sheba Medical Center
Tel Litwinsky, Israel